MyOme Posts Nine Roles After $200B Savings Forecast

The Bet Behind the Build

MyOme posted nine salaried and contract roles in a two-week window in late summer 2026, including Senior Scientist in Clinical Biostatistics, Wet Lab Staff Scientist, Senior Clinical Trial Manager, Commercial Contracts Counsel, and five others, as distribution deals converted its genome-first platform into orderable tests for thousands of providers. The Menlo Park company, founded in 2017, built its platform on Illumina's PCR-free whole-genome sequencing at a mean 30x coverage. The differentiator is not the sequencing but the interpretive layer on top: integrated polygenic risk scores (iPRS) that combine millions of variants with clinical factors, adjusted for ancestry through continuous decomposition rather than broad population buckets. The result is a risk assessment the company says works across diverse and admixed populations, a blind spot in earlier polygenic models. Tests run through a CLIA-certified, CAP-accredited lab and span proactive health screening (single-gene risks, medication response, polygenic scores for common conditions) and diagnostic panels for rare disease, including exome, genome, and copy-number analysis from a single sample.

The expansion signals growing demand for talent that can bridge clinical insight and software development, prompting applicants to highlight both technical depth and mission alignment. MyOme's screen is designed to filter for that hybrid competence explicitly, not to hope it emerges after hire.

Distribution Deals Trigger the Hiring Wave

A strategic collaboration and investment from Illumina, announced December 11, tied MyOme's risk models to the sequencer's population-scale roadmap and a clinical trial — the MPH study — designed to quantify healthcare savings from genome-first prevention. Modeling cited in the announcement projects more than $200 billion in annual U.S. savings if broad adoption materializes; the trial begins enrollment in 2026. Shortly after, partnerships with Ms.Medicine and Thatch embedded MyOme's proactive health test into primary-care workflows and employer benefits marketplaces. In March 2026, the Zenith portfolio launched with Natera, bringing rare-disease genome and exome analysis, plus long-read methylation analysis, to Natera's nationwide provider network. Methylation integration becomes automatic for eligible orders in early Q2 2026. April brought two board appointments: Sam Roosz and Dr. Ravi Thadhani.

Capital followed each milestone. A 2019 Series A (HOF Capital, Norwest) funded the lab build-out. A Series B closed December 2021 and announced June 2022. The Illumina strategic round arrived December 2025. A $10 million Natera add-on closed January 2026 under an amended Series B preferred agreement.

The Natera channel is the hiring catalyst. Its EMR integration footprint and high-complexity genomics infrastructure turn MyOme's assays into orderable tests for those providers. This Ms.Medicine and Thatch deals open primary-care and employer segments that previously had no practical path to genomic prevention. The MPH trial demands operational scale — sample logistics, bioinformatics throughput, clinical reporting, regulatory coordination — that a lean team cannot absorb. First-party board data confirms the response: eight salaried roles currently posted across engineering, commercial, research, and clinical operations. The company's careers page states the expansion plainly: "We're expanding our Engineering, Commercial, Research, and Clinical Ops teams."

This surge is not speculative growth. It is the operational consequence of distribution deals that convert technology into volume, and volume into the evidence base that reimbursement and guideline committees require.

Nine Roles, Two Weeks, One Trigger

MyOme posted nine distinct openings during that window in late August and early September 2026. The roles cluster around the Menlo Park headquarters, with additional positions in San Francisco, Charlotte, and remote arrangements. Eight carry salaried compensation; one is a contractor role. Zero G Talent's board data, which ingests listings directly from the source, shows a salary band across salaried roles, with the most recent postings commanding the upper end.

Genomics and Bioinformatics

Senior Scientist, Clinical Biostatistics & Genetic Risk Prediction (San Francisco; remote eligible) was posted August 30. This senior role sits at the core of MyOme's differentiated product: integrated polygenic risk scores validated across diverse ancestries. The title signals responsibility for statistical model development, validation across populations, and translation of genomic signals into clinical risk reports.

Scientist, Computational Biology (Menlo Park) was posted August 23. An individual-contributor position focused on algorithm development for whole-genome analysis pipelines. The "Scientist" title suggests a PhD-level hire with several years of postdoctoral or industry experience, tasked with optimizing variant calling, annotation, and interpretation workflows.

Bioinformatics Scientist/Biostatistician Contractor (Menlo Park) was posted September 5. The sole contractor role in the cohort, likely scoped to a defined project (perhaps ancestry-specific model refinement or a clinical trial deliverable). Contractor status implies a fixed-term need for specialized statistical genetics expertise without long-term headcount commitment.

Wet Lab and Laboratory Operations

Wet Lab Staff Scientist (Menlo Park) was posted September 5. "Staff Scientist" denotes a senior bench-level lead who owns assay development, library preparation optimization, and quality metrics for the whole-genome sequencing pipeline. This role bridges the wet lab and bioinformatics teams, ensuring sample-to-data fidelity.

Clinical and Medical Affairs

Senior Clinical Trial Manager (San Francisco; remote) was posted September 2. Manages the clinical trial referenced in MyOme's Illumina collaboration announcement (a study positioned to demonstrate healthcare cost savings). Responsibilities include protocol execution, site coordination, regulatory submissions, and cross-functional coordination with biostatistics.

Senior Medical Science Liaison (Charlotte; remote) was posted August 30. Field-facing role engaging clinicians, key opinion leaders, and health systems on MyOme's clinical utility evidence. The Charlotte base aligns with the company's stated focus on underserved communities in Alabama and the Southeast.

Regulatory, Legal, and Commercial

Commercial Contracts Counsel (San Francisco) was posted September 1. In-house legal role negotiating partnerships (e.g., Broad Clinical Labs), payer agreements, and vendor contracts. The salary band is the highest of the cohort, reflecting scarce dual expertise in commercial law and diagnostic reimbursement.

Revenue Cycle Specialist (Charlotte) was posted September 4. Operational role managing billing, coding, payer credentialing, and collections for a clinical laboratory. Charlotte placement suggests a billing-operations hub separate from R&D. No board salary data published for this role as of the latest scrape.

People Operations

Senior Human Resources Business Partner (Menlo Park; remote) was posted August 30. Strategic HR partner for engineering, research, and clinical teams during a headcount expansion phase.

The distribution reveals a deliberate balance: four senior bioinformatics/clinical roles anchoring the scientific core, two commercial-legal hires securing go-to-market infrastructure, one wet-lab lead protecting assay quality, and two operations roles (HR, revenue cycle) scaling the backend. The contractor role adds elastic capacity for a time-bound analytical push. All nine postings appeared within a two-week window, a compressed timeline that suggests a funding milestone or partnership trigger rather than steady-state backfill.

Inside the Screen: Code First, Culture Second

The interview topic distribution published by Interview Query — Data Structures & Algorithms (26), Machine Learning (18), SQL (13), Product Sense & Metrics (9), Behavioral (8) — reads like a weighted rubric. Data structures and algorithms lead by a wide margin, signaling that MyOme's engineering bar is set at classic computer-science depth, not just framework fluency. Machine Learning follows at roughly two-thirds the volume, reflecting the company's need to turn whole-genome sequences into polygenic risk scores and clinical interpretations. SQL and product sense appear at half the ML weight, suggesting candidates must also navigate the data plumbing and translate metrics into product decisions. Behavioral rounds, while the smallest counted category, still register eight distinct focus areas, enough to confirm culture is tested, not assumed.

MyOme's public messaging reinforces the cultural side of that rubric. The company describes itself as "mission-driven innovators" committed to "patient data ownership and fostering diversity within the workforce" and an "inclusive culture that values a variety of perspectives and encourages collective learning." Those phrases suggest the behavioral interviews assess whether candidates have operated in diverse teams, navigated ambiguous ownership questions, and prioritized patient interests over speed or revenue. The first-party board data shows open roles spanning wet-lab science, clinical biostatistics, medical affairs, and commercial contracts, roles that only collaborate effectively if shared values precede shared jargon.

Glassdoor's record for MyOme is thin: one anonymous interview review and zero posted questions as of the latest scrape. That scarcity means the Interview Query topic counts are the strongest public signal of what the screen actually tests. Candidates should treat the DSA and ML weights as non-negotiable preparation targets, but they would misread the process if they treated behavioral preparation as optional. The company's own language — "collective learning," "diversity of perspectives" — implies interviewers are calibrated to spot performative mission alignment. Candidates who demonstrate concrete examples of balancing technical rigor with patient-centered values will score higher than those who merely recite the mission statement.

The screening priority, in short, is hybrid competence: the algorithmic rigor to build scalable genomic pipelines, the statistical maturity to validate clinical predictions, and the cultural fluency to operate across lab, clinic, and product without losing the patient thread. That combination is rare enough that the screen filters for it explicitly, not expecting it to emerge after hire.

Writing the Application That Clears the Filter

MyOme's screen rewards specificity. The company's careers page explicitly seeks "mission-driven innovators to help transform healthcare through genomics," and the roles currently open — the wet-lab lead and senior clinical biostatistician focused on genetic risk prediction, clinical trial manager, medical science liaison — all sit at the intersection of deep technical execution and clinical translation. Candidates who treat the application as a generic bioinformatics submission will not clear the first filter.

Start with the cover letter. Industry guidance consistently recommends 3-4 paragraphs, 250-400 words, customized to the organization. For MyOme, that means opening with a direct connection to whole-genome sequencing in a clinical context, not a broad statement about loving genomics. Reference the company's focus on empowering individuals and providers through advanced genomic testing. If you have built pipelines that reduced variant-calling turnaround, say so with numbers: a 40% processing-time reduction, a 25% accuracy improvement, a pipeline that cut sequencing run errors by 25%. These metrics appear repeatedly in genomics cover letter templates because they map to the operational pressures MyOme faces scaling its testing capacity.

Mirror the technical vocabulary in the job postings. The ATS keyword lists for genomics scientist roles cluster around next-generation sequencing, whole-genome sequencing, RNA-seq, variant calling, GATK, SAMtools, Snakemake, Bioconductor, Python, R, multi-omics integration, clinical genomics, assay validation, and regulatory compliance. Weave these in naturally when describing your work; "developed a reproducible Snakemake pipeline for WGS variant calling that standardized QC metrics" carries more weight than "experience with bioinformatics pipelines." If you have CRISPR or gene-editing experience, include it; cover letter templates in the dataset frequently lead with CRISPR-based therapeutic projects that improved outcomes by 30% or more.

Demonstrate clinical fluency. MyOme's open roles include a senior clinical trial manager and a medical science liaison, which signals that the organization moves data toward patient-facing decisions. Candidates who have integrated genomic data with electronic health records, reduced genomic result turnaround for clinicians (one template cites 25%), or collaborated with cross-functional teams to translate multi-omics findings into biomarker candidates should foreground those projects. The research shows hiring managers in this sector explicitly look for "collaboration with cross-functional teams including computational biologists and clinicians" and "implementation of quality control, data management, and compliance with regulatory standards."

Quantify collaboration. Vague claims of "teamwork" fail. Instead, specify: "led a cross-disciplinary team to deliver a clinical-grade NGS panel validation under CLIA guidelines," or "partnered with oncology clinicians to define variant reporting thresholds that increased actionable findings." That data shows MyOme's salary bands reflect senior individual-contributor and lead expectations; they are hiring people who own outcomes, not just execute tickets.

Avoid the failure patterns that appear across every genomics hiring guide: generic openings ("I am writing to apply for..."), focusing on what you want from the role rather than what you contribute, excessive jargon without explanation, omitting the recipient's title, and failing to connect your background to the organization's stated goals. One guide flags "using an unprofessional email address" and "providing incorrect contact information" as still-common disqualifiers, basics that suggest attention-to-detail screening is real.

Close with a concrete next step. "I would welcome the opportunity to discuss how my WGS pipeline optimization experience could support MyOme's clinical reporting timelines" beats "I look forward to hearing from you." The screen is designed to find people who already think like MyOme employees: clinical, quantitative, mission-aligned. Write the application that proves you do.

A Sector Expanding While Capital Retreats

MyOme's nine-role hiring burst arrives at a contradictory moment for the genomics labor market. The global genomics workforce surpassed 752,000 in 2024 with 58,000 net new hires over the prior year, and the market itself is projected to nearly quadruple, a 16.5% compound annual growth rate, per Precedence Research. Yet U.S. life sciences employment contracted 0.3% in 2024 after 2023's growth slowed to just 1.2%, down from a five-year average of 4.5%. Series A funding fell 46% year-over-year in 2023, and new unicorn formation dropped 58%. Venture-backed IPOs are on track for their lowest level since 2016, with U.S. exit value down 86% from the 2021 peak. The macro picture is a sector expanding in revenue and scientific ambition while the capital that fuels early-stage headcount growth has retreated sharply.

The divergence sharpens when you slice by sub-sector. Computational genomics (the niche where MyOme operates) grew its headcount 8% annually to roughly 1,800 people across 43 companies, adding 220 roles in the last year. Genomic analysis expanded 5.9% to 11,000 employees. Functional genomics, by contrast, shed workers at a -2.4% clip despite employing 19,000. The pattern is clear: demand is concentrating where wet-lab biology meets heavy compute. The National Security Commission on Emerging Biotechnology noted that once models can become as fluent in DNA and other biological molecules as they now are in human language, the results will be profound. Deepa Pandey, principal consultant at Precedence Research, said: "The integration of AI in genomic pipelines is no longer a luxury, it's a necessity for precision drug development." That convergence is rewriting job descriptions across the board. BIO's 2025 industry survey found AI literacy ranked as a top priority on the healthcare side of life sciences, while data management and quality control skills led in medical devices and agriculture.

Geographically, the center of gravity is shifting. Asia-Pacific emerged in 2025 as the fastest-growing hub for biotech employment, driven by China's double-digit industry growth, India's bioeconomy targeting $150 billion, and Singapore's "Biopolis" model. APAC now runs nearly half of new global clinical trials. Australia faces a 35% talent shortfall in digital and data-driven roles. Nearly four in five APAC employers reported difficulty filling positions in 2025, with bioinformatics and AI-driven drug discovery among the acute gaps. Chinese-born researchers are returning from the U.S. and Europe in large numbers, drawn by grants and roles at home, a "reverse brain drain" that tightens the U.S. pipeline further. North America still held 42.7% of the genomics market in 2024, but its CAGR of 16.6% trails APAC's 18.1%.

The talent crunch shows up in compensation. MyOme's posted bands sit squarely in the startup tier for senior bioinformatics and clinical roles, competitive with peers but well below the AI-lab ceiling.

For a company like MyOme, the strategic implication is twofold. First, the candidate pool for hybrid bioinformatics-clinical roles is structurally small relative to demand; computational genomics added just 220 people globally last year. Second, the screening bar has risen: "T-shaped" professionals who combine deep domain expertise with Python/R, LIMS, and cloud-native data pipelines are the scarce commodity. BIO reports companies are responding by narrowing hiring to "strategic" roles, leaning harder on contractors, and investing in incumbent upskilling. MyOme's push for nine hires across engineering, bioinformatics, and product in a single cycle signals confidence that it can attract that hybrid profile before the APAC talent engine and Big Tech compensation gravity absorb the remaining supply.

The Wet Lab Staff Scientist Who Owns the Fidelity

The role posted last — Wet Lab Staff Scientist, Menlo Park — sits at the seam where sample becomes data. Every risk score MyOme reports, every methylation call Natera orders, every MPH trial endpoint traces back to library prep quality that this hire will own. The screen that filters for algorithmic rigor and clinical fluency ultimately serves this benchmark: can the candidate protect the fidelity that makes the rest of the platform credible?

Working in frontier tech? Zero G Talent tracks the openings: see every open MyOme role, browse frontier tech jobs, the companies hiring, and the people building the field.